Page 42 - SaxoCell Annual Report 2021
P. 42
HemRec
The HemRec project is based on the development of proprietary designer recombinases
by the group of Frank Buchholz (TUD). The platform technology has already been
incorporated into a spin-off company (RecTech GmbH) founded during the first funding
period.
SaxoCell Projects Within the SaxoCell project "HemRec", the team plans to develop a generally applicable
designer-recombinase based healing strategy for ß-chain hemoglobinopathies. This
designer-recombinase is intended to excise a small DNA fragment from hematopoietic
stem cells of diseased patients, ultimately leading to the reactivation of gamma-globin
and thus to the long-term production of healthy red blood cells.
To achieve this goal and to clinically translate the project, the research group started
working closely with the DKMS Life Science Lab. Its strength lies in the safe and flexible
genome editing.
Project Manager: Prof. Dr. Frank Buchholz
Project Partners: Technical University Dresden, DKMS Life Science Lab gGmbH
37
